Increasing evidence suggests that autoantibodies can precede symptomatic autoimmune disease by several years.[17] ANA testing holds significant clinical relevance in assessing the activity of autoimmune disease, monitoring treatment efficacy, and guiding clinical medication.[18]. The gene discussed is BTG3; the disease is autoimmune disease.